Coronary Artery Disease, Heart Diseases
Conditions
Keywords
coronary artery bypass surgery, multiple arterial graft, radial artery graft
Brief summary
The primary hypothesis of ROMA is that in patients undergoing primary isolated non-emergent coronary artery bypass surgery (CABG), the use of two or more arterial grafts compared to a single arterial graft is associated with a reduction in the composite outcome of death from any cause, any stroke, post discharge myocardial infarction and/or repeat revascularization. The secondary hypothesis is that in patients undergoing primary isolated non-emergent CABG, the use of two or more arterial grafts compared to a single arterial graft is associated with improved survival. Prospective event-driven unblinded randomized multicenter trial of at least 4,300 subjects enrolled in at least 25 international centers. Patients will be randomized to a single arterial graft (SAG) or multiple arterial grafts (MAG). Patients will be randomized in a 1:1 fashion between the two groups. Permuted block randomization with random blocks stratified by the center and the type of second arterial graft will be used to provide treatment distribution in equal proportion.
Detailed description
In the 1980's, it was recognized that long-term survival was enhanced in patients undergoing coronary surgery when the left anterior descending (LAD) was grafted with a left internal thoracic artery (ITA) rather than a saphenous vein (1). This difference was predicated, at least in part, due to greater and more durable patency of the left ITA compared to an increased early occlusion rate and later progressive atherosclerosis of saphenous vein grafts (SVG) (2). For more than 20 years it has generally been accepted that patients who receive multiple arterial grafts (AGs) at the time of coronary artery bypass surgery (CABG) have increased postoperative survival compared to those who receive only one AG, especially over the long term (3-5). The current United States and European Guidelines encourage the use of AGs in patients with a long life expectancy (6, 7). Last year, a position paper from the Society of Thoracic Surgeons strongly recommended a wider use of AGs (8). The putative mechanism underlying the AG hypothesis is greater patency. In line with the original findings of improved LAD graft patency with ITA vs. SVG, data from randomized control trials (RCTs) as well as observational studies and a network meta-analysis (9) have demonstrated that the patency of the RA, as well as the right ITA, exceed that of a SVG, providing mechanistic basis to support the AG hypothesis. ROMA is a two arm event driven randomized multi-centre trial aimed at evaluating the impact of the use of one ITA vs two or more AGs for CABG on a composite of death from any cause, any stroke, post discharge myocardial infarction and/or repeat revascularization. The trial is powered to detect a 20% relative reduction in the primary outcome with 90% power at 5% alpha. The primary aim is to conduct a multicenter international randomized control trial to test the hypothesis that the use of a two or more AGs compared to a single arterial graft is associated with a reduction in the composite outcome of death from any cause, any stroke, post discharge myocardial infarction and/or repeat revascularization. The secondary aim is to conduct a multicenter international randomized control trial to test the hypothesis that the use of two or more AGs compared to a single arterial graft is associated with improved survival.
Interventions
PROCEDURESingle arterial graft
This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
PROCEDUREMultiple arterial grafting
This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
Sponsors
Weill Medical College of Cornell University
National Heart, Lung, and Blood Institute (NHLBI)
Canadian Institutes of Health Research (CIHR)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
The endpoint assessors will be blinded to treatment allocation (PROBE).
Intervention model description
Patients undergoing coronary artery bypass surgery will be in one of two groups. One group will receive a single arterial graft and the second group will receive two or more arterial grafts.
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Primary isolated CABG patients with disease of the left main coronary artery and/or of the left anterior descending and the circumflex coronary system with or without disease of the right coronary artery.
Exclusion criteria
* Age \> 70 years * Single graft * Emergency operation * Evolving myocardial infarction within 48 hours of surgery * Left ventricular ejection fraction of \< 35% * Any concomitant cardiac or non-cardiac procedure * Previous cardiac surgery * Preoperative severe end-organ dysfunction (dialysis, liver failure, respiratory failure), cancer or any co-morbidity that reduce life expectancy to less than 5 years. * Inability to use the saphenous vein or to use both radial and right internal thoracic arteries * Anticipated need for coronary thrombo-endarterectomy * Planned hybrid revascularization
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Composite Outcome | > 72 hours after surgery and/or repeat revascularization | A composite of death from any cause, any stroke, post discharge myocardial infarction and/or repeat revascularization. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 30-day mortality | 30 days post-operatively | Death from any cause at 30-days |
| Major postoperative complications | In-hospital stay, up to 30 days post-operatively | Revision for bleeding, perioperative myocardial infarction, any stroke, need for dialysis, need for tracheostomy, and surgical site infection. |
| Sternal wound complication | 6 months post-operatively | Wound drainage, skin separation, unstable sternum, and sternal dehiscence, infection |
| Composite Outcome of Death from any cause | Analysis will be performed after 631 events. The investigators assume this will occur at a mean follow-up of 5 years. | A composite of death from any cause, post discharge myocardial infarction,stroke, and/or repeat revascularization |
| Stroke | Analysis will be performed after 631 events. The investigators assume this will occur at a mean follow-up of 5 years. | Post discharge myocardial infarction and repeat revascularization considered as individual events |
| Cause-specific death (cardiac vs non-cardiac) | Analysis will be performed after 631 events. The investigators assume this will occur at a mean follow-up of 5 years | Death as either cardiac or non-cardiac in etiology |
| Hospital readmissions | Analysis will be performed after 631 events. The investigators assume this will occur at a mean follow-up of 5 years | Hospital readmissions with specific causes |
Countries
Austria, Brazil, Canada, China, Croatia, Czechia, Germany, Italy, Japan, Netherlands, Poland, Portugal, Serbia, Singapore, South Korea, Spain, United States
Contacts
CONTACTMario Gaudino, MD
CONTACTMarshagay Rodriques
PRINCIPAL_INVESTIGATORMario Gaudino, MD
Weill Medical College of Cornell University
PRINCIPAL_INVESTIGATORStephen Fremes, MD
Sunnybrook Health Sciences Centre
Outcome results
None listed